Call us : +91-11-2874-2874   |   Email us : info@translumina.in

Clinical Data

Clinical Data

Excellent Safety Profile

At 4 years follow up Yukon Choice PC showed reduction of risk by 50% in definite Stent Thrombosis and by 78% in Very Late Thrombosis compared to First generation DES without compromising on efficacy. This was published in March 2012 issue of the European Heart Journal . Meta-analysis of 4000 patients which compared biodegradable polymer based DES with permanent polymer based DES was used to arrive at this conclusion to establish excellent safety profile of Yukon Choice PC.


Know More
 

Equivalence to Gold Standards

Yukon Choice PC proved equivalence to Xience and Cypher in terms of late loss, binary restenosis, TLR and primary composite MACE at 3 Years follow up published in September’ 2011 issue of JACC . Yukon Choice PC has been able to achieve this despite using minimal polymeric load of bio degradable polymer. This proves that a Microporous stent surface which acts as small reservoir for drug, enables very less of polymer to deliver drug to the targeted tissues adequately in place of large amount of permanent polymer which has been used in first generation stents.


Know More
 

Proven Concept

Pre-Clinical studies conducted on Yukon Choice PC was published in October’ 2008 issue of Biomaterials which proves it’s safety and efficacy over BMS and conventional DES and generates hypothesis which forms the basis of large prospective randomized clinical trials. Pre clinical studies conducted on Yukon Choice PC . Yukon Choice PC showed significant tissue concentration of Sirolimus in arterial segments for anti-restenotic activity implanted in porcine coronary artery .It has also shown reduced neointimal formation compared to bare metal stent without compromising on vascular healing.


Know More
 

Safety on BMS Platform

The objective of this study was to examine the relationship between stent surface topography and outcome in patients undergoing implantation of stents with rough and smooth surfaces. Surface topography is considered an important determinant of the bare stent performance. Specifically designed rough surface may increase the drug storing capacity of stents but its direct impact on the risk of thrombosis and restenosis is not known.


Know More